Category

• Pipeline1
• Research1

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• AMD2
• Glaucoma2
• Alzheimer's Disease1
• Clinical Trials1
• Neurodegenerative Disease1
• Retina1

• Organizations: Galimedix Therapeutics✕

Clear all

Pipeline

Galimedix kicks off phase 1 study on oral therapy for ocular neurodegenerative diseases

Trial will evaluate GAL-101, an amyloid beta aggregation modulator designed to provide neuroprotection and improve visual function to dry AMD and glaucoma.

Research

Théa Open Innovation, Galimedix collaborate for GAL-101 development and commercialization

Novel treatment for dry AMD and glaucoma aims to provide neuroprotection and improved visual function.